Clinical trials: Multiple Myeloma (MM)
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Sleep Apnea in Patients With MGUS and MM
This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens.
- Trial name
- NCT04114084
- Testing
- Bone Marrow Aspirate and Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Michael Tomasson
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Multiple Myeloma
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) in combination with…
- Trial name
- CyBorD-Dara (NCT02955810)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- National University of Ireland, Galway, Ireland
Elranatamab, Myeloma
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma.
- Conditions
- Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT05228470
- Testing
- Elranatamab
- Where
- 15 sites in China
- Volunteers
- 39 people
- Sponsor
- Pfizer
Blood Cancers, Leukemia
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth.
- Conditions
- Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant
- Trial name
- NCT07814170
- Testing
- A manualised post-traumatic growth intervention for people with hematological cancers
- Where
- 2 sites in Greece
- Volunteers
- 80 people
- Sponsor
- University of West Attica
Multiple Myeloma
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients
The objective of this study is to evaluate the immune profile of plasma cells and immune effector cells in paired peripheral whole blood and bone marrow samples from MM patients by standardized flow cytometry.
- Trial name
- MYELOME-MM (NCT05428163)
- Testing
- Biological sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Multiple Myeloma
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization).
- Trial name
- DRAMMATIC (NCT04071457)
- Testing
- Lenalidomide, Daratumumab/rHuPH20
- Where
- 842 sites in United States, Canada
- Volunteers
- 1,100 people
- Sponsor
- SWOG Cancer Research Network
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
Multiple Myeloma
Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis
The purpose of this study is to present a descriptive analysis of demographic and clinical characteristics of the participants, as well as of the treatment patterns for multiple myeloma (MM) in Brazil.
- Trial name
- MMyBRave (NCT03506386)
- Testing
- No Intervention
- Where
- 17 sites in Brazil
- Volunteers
- 943 people
- Sponsor
- Takeda
Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory…
- Trial name
- NCT07101705
- Testing
- OriV508 Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma, AL Amyloidosis
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL).
- Trial name
- NCT07638683
- Testing
- Teclistamab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma, Renal Impairment
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and…
- Trial name
- POM Renal (NCT01575925)
- Testing
- 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Celgene
AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried…
- Trial name
- Soursop (NCT07771803)
- Testing
- Soursop tea
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roger Strair
Multiple Myeloma
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
Multiple myeloma patients often get serious infections that can be deadly. A British study looked at newly diagnosed patients and found that bacterial infections were the main cause of death in the first 60 days, mostly from…
- Trial name
- NCT07154537
- Testing
- 2-dose PCV13, 1-dose PCV13
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis, Multiple Myeloma
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in…
- Trial name
- NCT05775094
- Testing
- Romosozumab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.
- Trial name
- NCT02272803
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608)
- Where
- 28 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture.
- Trial name
- NCT06759181
- Testing
- anti-BCMA/FcRL5 CAR T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Multiple Myeloma (MM), GI Cancer
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation.
- Conditions
- Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)
- Trial name
- GustaborRCT (NCT07649681)
- Testing
- Gustabor server, Standard Recommendations
- Where
- 6 sites in Germany
- Volunteers
- 198 people
- Sponsor
- Wuerzburg University Hospital
Newly Diagnosed Multiple Myeloma
A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM
This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.
- Trial name
- NCT05088330
- Testing
- Daratumumab
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University